Trade Corvus Pharmaceuticals, Inc. - CRVS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0332 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.7184 |
| Open | 4.6384 |
| 1-Year Change | 124.65% |
| Day's Range | 4.6384 - 5.0884 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 4.9884 | 0.3600 | 7.78% | 4.6284 | 5.0984 | 4.6084 |
| Jan 16, 2025 | 4.7184 | -0.1500 | -3.08% | 4.8684 | 4.8784 | 4.5884 |
| Jan 15, 2025 | 4.8984 | -0.2200 | -4.30% | 5.1184 | 5.2184 | 4.8684 |
| Jan 14, 2025 | 5.0884 | -0.0300 | -0.59% | 5.1184 | 5.2684 | 4.9784 |
| Jan 13, 2025 | 5.1584 | -0.0900 | -1.71% | 5.2484 | 5.2684 | 5.0684 |
| Jan 10, 2025 | 5.3084 | -0.1700 | -3.10% | 5.4784 | 5.4884 | 5.2284 |
| Jan 8, 2025 | 5.6284 | -0.1100 | -1.92% | 5.7384 | 5.7684 | 5.5184 |
| Jan 7, 2025 | 5.7484 | -0.2700 | -4.49% | 6.0184 | 6.0684 | 5.7384 |
| Jan 6, 2025 | 6.0184 | 0.1500 | 2.56% | 5.8684 | 6.4384 | 5.8084 |
| Jan 3, 2025 | 5.8184 | 0.4700 | 8.79% | 5.3484 | 5.9184 | 5.2384 |
| Jan 2, 2025 | 5.4184 | 0.0900 | 1.69% | 5.3284 | 5.6384 | 5.2384 |
| Dec 31, 2024 | 5.3384 | 0.1300 | 2.50% | 5.2084 | 5.3384 | 4.9684 |
| Dec 30, 2024 | 5.2384 | 0.2300 | 4.59% | 5.0084 | 5.2584 | 4.9184 |
| Dec 27, 2024 | 5.1984 | 0.0400 | 0.78% | 5.1584 | 5.3684 | 5.0884 |
| Dec 26, 2024 | 5.2784 | 0.4000 | 8.20% | 4.8784 | 5.3784 | 4.8784 |
| Dec 24, 2024 | 4.8884 | 0.3400 | 7.48% | 4.5484 | 4.9184 | 4.4984 |
| Dec 23, 2024 | 4.5384 | -0.3200 | -6.59% | 4.8584 | 4.8784 | 4.5084 |
| Dec 20, 2024 | 4.9884 | 0.0500 | 1.01% | 4.9384 | 5.3084 | 4.7184 |
| Dec 19, 2024 | 5.0784 | 0.5300 | 11.65% | 4.5484 | 5.0784 | 4.2884 |
| Dec 18, 2024 | 4.6884 | -0.3000 | -6.01% | 4.9884 | 5.1784 | 3.7584 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Corvus Pharmaceuticals, Inc. Company profile
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.
| Industry: | Biotechnology & Medical Research (NEC) |
863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com